In essence, NPM1-ALK is able to activate a number of pathways that confer the hallmarks of cancer on incipient tumour cells [10] including pathways that facilitate increased survival and reduced apoptosis, such as the mitogen-activated protein kinase (MAPK) [11], phosphoinositide 3-kinase (PI3K)-Akt [12], Janus kinase (JAK)-signal transducer and activator of transcription (STAT) [13] and phospholipase C gamma (PLCγ) pathways [14] (Figure 2). The gene discussed is ALK; the disease is neoplasm.